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A B S T R A C T
GABA (g-amino butyric acid) receptors have always been an inviting target in the etiology and treatment
of epilepsy because of its role as a major inhibitory neurotransmitter in the brain. The aim of our study
was to ﬁnd out the possible role of single nucleotide polymorphisms (SNPs) present in GABRA1
IVS11 + 15 A > G (rs2279020) and GABRG2 588C > T (rs211037) genes in seizure susceptibility and
pharmaco-resistance in northern Indian patients with epilepsy. A total of 395 epilepsy patients and 199
control subjects were enrolled for present study. The genotyping was done by PCR-RFLP methods. The
GABRA1 IVS11 + 15 A > G polymorphism conferred high risk for epilepsy susceptibility at genotype ‘AG’
(P = 0.004, OR = 1.77, 95% CI = 1.20–2.63), ‘GG’ (P = 0.01, OR = 1.80, 95% CI = 1.15–2.80) and G allele level
(P = 0.001, OR = 1.50, 95% CI = 1.16–1.92). Moreover this polymorphism was also associated with
multiple drug resistance in patients with epilepsy for homozygous variant ‘GG’ genotype (P = 0.031,
OR = 1.84, 95% CI = 1.05–3.23) and G allele (P = 0.020, OR = 1.43, 95% CI = 1.05–1.95). However GABRG2
588C > T polymorphism was not found to be associated either with epilepsy susceptibility or with drug
resistance. Overall results indicate differential role of different subunits of GABAA receptor subtypes in
epilepsy susceptibility and pharmacotherapy.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is most common paroxysmal and heterogeneous
neurological disorder affecting an estimated 42 million people
worldwide with distinct symptoms, etiology, prognosis and
treatments.1 Overall prevalence of epilepsy roughly lies in the
range of 5–10 per 1000 people, which is usually higher in
developing countries.2,3 Majority of epilepsy phenotypes result
from interaction between genes and environmental factors. It is
just over a decade since the discovery of the ﬁrst human epilepsy
associated ion channel gene mutation, at least 25 different genes
have been described till now, although the strength of the
evidences for these genes having a pathogenic role in epilepsy
varies. Only 1–2% idiopathic epilepsies seem to be monogenic;
whereas most of them are believed to be polygenic.4 These gene
and their variants inﬂuence seizures, epileptogenesis and epilepsy
at multiple levels.5 Therefore, genes encoding voltage gated Na+,
K+, Ca++, Cl and HCN,6,7 and ligand-gated (nicotinic acetylcholine
and GABA receptors) ion channels are considered to be major class
of genes associated with various epilepsy phenotypes.* Corresponding author. Tel.: +91 522 2668700x2322; fax: +91 522 2668017.
E-mail addresses: balraj@sgpgi.ac.in, bml_pgi@yahoo.com (B. Mittal).
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.02.009In the central nervous system, GABA is the major inhibitory
neurotransmitter that controls neuronal excitability and network
interactions in the cerebral cortex of the brain. It acts through
three receptor classes: the ionotropic GABAA, GABAC receptors
and the metabotropic GABAB receptors. Among the three
receptors, recent ﬁndings highlight the signiﬁcance of GABAA
receptor heterogeneity for the concept of E/I (excitation/inhibi-
tion) balance and its relevance for epilepsy.8 Structurally GABAA
receptors are pentameric chloride ion channels formed from
various combinations of proteins encoded by a (a1–a6), b (b1–
b3),g (g1–g3);d, e,p, u, andr (r1–r3) subunit gene families. The
a1b2g2 subunit combination of GABAA receptor is most
abundant in almost all regions of the brain.3 Dysfunction of
genes coding these subunits affects ion channel gating, expres-
sion, and trafﬁcking of the GABA receptor to the cell surface. These
genes are also believed to inﬂuence important drug targets
necessary for the regulation of neuronal activity in the brain.9
Antiepileptic drugs (AEDs) such as benzodiazepines, phenobar-
bital, gabapentin and topiramate are important targets of GABAA
receptor.10 Recently it has been reported that AED resistant rats
differ from drug responsive rats in GABAA receptor subunit
expression in rat model of temporal lobe epilepsy. It also suggests
that alterations in GABAA receptor subunits may be involved in
resistance to AEDs.11vier Ltd. All rights reserved.
Fig. 1. (a) Schematic diagram showing location of GABRA1 gene polymorphisms. (b) Schematic diagram showing location of GABRG2 gene polymorphisms.
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described so far but only few including intronic GABRA1
IVS11 + 15 A > G and an exonic GABRG2 588C > T gene poly-
morphisms are found to have functional signiﬁcance in different
neurological disorders. These gene variants have been attributed as
one of the several susceptibility factors for febrile seizures9,12; with
the development of alcoholism and substance abuse disorders
affecting neuronal channels.13,14
Thus, genes encoding GABAA receptor subunits represent high
ranking candidates for epilepsy susceptibility and targets for
pharmacotherapeutic agents in epilepsy treatment. Therefore, on
the basis of functional signiﬁcance, previous observations and
current knowledge we investigated the possible role of these
genetic polymorphisms GABRA1 IVS11 + 15 A > G (rs2279020) and
GABRG2 588C > T (rs211037) [Fig. 1(a) and (b)] in epilepsy
susceptibility and antiepileptic drug (AED) response in northern
Indian patients with epilepsy.
2. Materials and methods
2.1. Patients and controls
Epilepsy patients were enrolled from the outpatients depart-
ment (OPD) of neurology attending the clinics of Sanjay Gandhi
Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow,
India. The patients were diagnosed and classiﬁed by an experi-
enced neurologist. The clinical proﬁle of drug responsive and drug
resistant epilepsy patients were based on hospital investigations.
Exclusion criteria included severe adverse drug reactions; poor
compliance with AEDs, unreliable record of seizure frequency,
history of pseudo seizures, alcohol or drug abuse, or any other
malignant diseases such as brain tumor, secondary metastasis,
hepatic failure or renal failure. An informed consent was signed by
each participant or responsible adult and they were personally
interviewed for information on ethnicity, seizure frequency, and
duration of seizure, compliance and other habits. After screening of
more than 500 patients a total of 395 patients were included rest
were excluded. 259 patients were diagnosed as drug responsive
and 122 are nonresponsive. We found that in responders group,
123 (45.1%) patients were on monotherapy and 150 (54.9%) were
on polytherapy, i.e. on more than two drugs. In case of
nonresponsive epilepsy patients, all were undergoing polytherapy.
It was observed that patients who respond early to treatment are
less likely to become drug resistant. There appears to be nosigniﬁcant differences in response when compared on the basis of
monotherapy and polytherapy. Fourteen patients showed only
partial response and therefore excluded from the study analysis
involving drug response.
A total of 199 healthy controls were recruited from staff of
SGPGIMS and unrelated persons from north India visiting the
hospital for minor medical or surgical problems, reported no
history of epileptic seizures, and other brain abnormalities. All
controls, drug resistance and drug responsive patients were of
same ethnic origin. The study was approved by local ethics
committee of the institute at SGPGIMS, Lucknow, India.
2.2. Deﬁnition of drug resistance and responsiveness
The main criterion for drug resistance was the occurrence of at
least four seizures over a period of one year with three appropriate
antiepileptic drugs (AEDs) at maximum tolerated doses.15,16
Patients who had under-gone surgeries for seizure control were
considered refractory irrespective of their outcome after surgery.
The epilepsy patients who had complete freedom from seizures for
at least one year from last follow up visit were considered drug
responsive.
In order to ascertain drug compliance, antiepileptic drug levels
in plasma were measured using HPLC (Perkin Elmer) in 20% of
patients to conﬁrm compliance and all patients enrolled in the
study showed drug compliance. Mean carbamazepine, phenytoin
and valproate levels were 8.26  5.25 mg/ml, 11.27  8.12 mg/ml
and 68.0  36.22 mg/ml respectively in epileptic patients; and were
in therapeutic range. Themaximum tolerated doseswere different for
different individuals in our epilepsy patients. These were 20 mg/kg/
day for carbamazepine, 20 mg/kg for phenytoin and 10 mg/kg for
valproate.
2.3. Laboratory protocols
2.3.1. Genotyping of GABRA1 (rs2279020) and GABRG2 (rs211037)
The genomic DNA was extracted from peripheral blood
leucocytes pellet using the standard salting out method with
slight modiﬁcations.17 The plasma was separated and stored at
20 8C for drug level assay. We genotyped total 395 epilepsy
patients and 199 healthy controls. Genotyping was performed
using PCR-RFLP method as reported previously (Table 1). Twenty
percent of samples from patients including samples of each
genotypewere re-genotyped by different laboratory personnel and
Table 1
List of primers used.
SNP Primer sequence Restriction enzyme Reference
GABRA1 IVS11+15 A>G (rs2279020) F 50-GCT ATG GAT TGG TTT ATT GCC GTG TG-30 AvaII 14
R 50-ATA ATA TTG ATG TAC TAC AGG GAC-30
GABRG2 588C>T (rs211037) F 50-AATCACCTTTTATTCTAATGGTC-30 ApoI 9
R 50-CAGTGAAGGCAACTTACTAAGA-30
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ing. PCR reaction was carried out in ﬁnal volume of 20 ml
containing 50–100 ng genomic DNA. PCR conditions were as
follows: a denaturing step at 95 8C for 5 min, then 30 cycles at 94 8C
for 30 s, annealing temperature 60 8C for GABRA1 IVS11 + 15 and
57 8C for GABRG2 588C > T for 30 s, 72 8C for 30 s, and a ﬁnal
extension at 72 8C for 7 min. After ampliﬁcation, PCR products of
165 bp and 122 bp observed respectively; which were digested
using speciﬁc restriction endonuclease. The AvaII (Fermentas Inc.,
USA) RFLP assay in GABRA1 IVS11 + 15 A > G polymorphism was
used to distinguish the A/G substitution at nucleotide 15 of the last
intron and the products were separated by using 15% poly-acryl
amide gel electrophoresis and genotyping patterns were recorded.
For GABRA1 IVS11 + 15 polymorphism genotypeswere classiﬁed as
‘AA’ homozygote 165 bp, ‘AG’ heterozygote 165 bp and 141 bp, and
‘GG’ homozygote 141 bp (Fig. 2). The GABRG2 588C > T
polymorphism containing PCR product of 122 bp was digested
with ApoI restriction enzyme (NEB Inc., USA) at 57 8C in total
volume of 10ml. After restriction digestion with ApoI; the T alleleFig. 2. Representative gel picture for GABRA1 IVS11 + 15 A > G (rs2279020)
genotyping; lane 1, 50 bp DNA ladder; lane 2, homozygous AA genotype; lane 3,
heterozygous AG genotype; lane 4, homozygous GG genotype.
Fig. 3. Representative gel picture for GABRG2 588C > T (rs211037) genotyping. Lane
1, undigested; lane 2, DNA ladder; lane 3, homozygous CC genotype; lane 4,
heterozygous CT genotype; lane 5, homozygous TT genotype.produced two fragments of 102 bp and 20 bp and stained with
ethidium bromide (Fig. 3). Gel documentation was done using
Alpha imagerTM 1220, Alpha Innotech Corporation, and San
Leandro, CA.
2.4. Statistical analysis
The relationship between various genotypes and responsive-
ness was examined using binary logistic regression. Association
was expressed as odds ratios (OR) or risk estimates with 95%
conﬁdence intervals (CI). The signiﬁcant association was con-
sidered when P-value was <0.05. All analyses were performed
using the SPSS statistical analysis software, version 15.0 (SPSS,
Chicago, IL, USA). The sample size was calculated using the
QUANTO 1.1 program (http://hydra.usc.edu/gxe). Desired power
of studywas set 80%. Relative risks for power calculation were set
at 2.
3. Results
The mean age  SD of patients with epilepsy was 24.25  11.65.
Among all the patients with epilepsy, 72.2% (285/395) were male and
27.8% (110/395) were female. Patients were also categorized on the
basis of their drug response status. Themean age of the drug resistant
patientswas 23.84  11.94 years versus drug responsive patientswas
24.72  11.24 years. Epilepsy was classiﬁed as symptomatic, idio-
pathic, or cryptogenic. Seizures were classiﬁed as generalized or
partial; 57.5% (227/395) had generalized seizures, whereas 42.5%
(168/395) had partial seizures. Mean age of onset for seizures in
epilepsy patients was 16.39  10.71 years. We were not able to
correlate drug levels in patients with genotypes because sample size
was very small for the given drugs and particular genotypes.
Among responders 116 (44.8%) were found to have sympto-
matic and 143 (55.2%) idiopathic epilepsy. Similarly among drug
resistant group 58 (47.5%) were having symptomatic epilepsy and
64 (52.5%) exhibited idiopathic epilepsy.
3.1. Association of GABRA1 A > G and GABRG2 588C > T gene
polymorphisms and susceptibility to epilepsy
We analyzed the genotype and allelic frequencies in 395
sporadic epilepsy patients and 199 control subjects by PCR-RFLP
assay (Tables 2 and 3). Genotype and allelic frequencies of GABRA1
IVS11 + 15 A > G and GABRG2 588C > T polymorphisms studied
were consistent with Hardy–Weinberg equilibrium (P = 0.730) in
our control population. Frequencies of AG and GG genotypes of
GABRA1 IVS11 + 15 A > G were found to be signiﬁcantly higher in
epilepsy patients versus control subjects for AG (P = 0.004,
OR = 1.77, 95% CI = 1.20–2.63), GG (P = 0.010, OR = 1.80, 95%
CI = 1.15–2.80) genotype as well as for variant G allele
(P = 0.001, OR = 1.50, 95%, CI = 1.16–1.92) (Table 2). However,
for GABRG2 588C > T gene polymorphism we did not observe any
signiﬁcant differences in genotype or allelic frequencies between
the epilepsy and control subjects (Table 3).
After Bonferroni correction for multiple testing, reference P-
value became 0.01 where it was 0.001 (Table 2 for ‘G’ allele); and
for AG genotype for which P-value became 0.04, in both cases it is
Table 2
Distribution of GABRA1 (rs2279020) polymorphism in epilepsy patients versus healthy controls and drug responsive versus drug resistant epilepsy.
Genotypes/
allele
Control subjects
(N=199)
Epilepsy patients
(N=395)
P-Value OR
(95% CI)
Drug responsive
(N=259)
Drug resistant
(N=122)
P-Value Odds ratio
(95% CI)
AA 94 (47.23%) 132(33.41%) Reference Reference 92(35.52%) 34 (27.86%) Reference Reference
AG 63(31.65%) 157(39.74%) 0.004 1.77(1.20–2.63) 107(41.31%) 47 (38.52%) 0.517 1.18(0.70–2.00)
GG 42(21.10%) 106(26.83%) 0.010 1.80(1.15–2.80) 60(23.16%) 41(33.60%) 0.031 1.84(1.05–3.23)
A* 251 (63.06%) 421 (53.29%) Reference Reference 291(56.18%) 115(47.13%) Reference Reference
G* 147 (36.93%) 369 (46.71%) 0.001 1.50(1.16–1.92) 227(43.82%) 129(52.87%) 0.020 1.43(1.05–1.95)
Table 3
Distribution of GABRG2 (rs211037) polymorphism in epilepsy patients versus healthy controls and responsive versus refractory epilepsy.
Genotypes/
allele
Healthy controls
(N=199)
Epilepsy patients
(N=395)
P-Value Odds ratio
(95% CI)
Drug responsive
(N=259)
Drug resistant
(N=122)
P-Value Odds ratio
(95% CI)
CC 117(58.79%) 211(53.41%) Reference Reference 137(52.89%) 66 (54.09%) Reference Reference
CT 73(36.68%) 168(42.53%) 0.179 1.28 (0.89–1.82) 109(42.08%) 53 (43.44%) 0.967 1.01(0.65–1.57)
TT 9(4.52%) 16(4.05%) 0.974 0.99 (0.42–2.30) 13(5.01%) 3(2.45%) 0.263 0.48(0.13–1.74)
C* 307 (77.13%) 591(74.68%) Reference Reference 383(73.94%) 185(75.81%) Reference Reference
T* 91 (22.86%) 199(25.31%) 0.379 1.14 (0.85–1.51) 135(26.06%) 59(24.18%) 0.578 0.91(0.64–1.29)
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in case of GG genotype signiﬁcance disappeared after Bonferroni
correction.
3.2. GABRA1 (rs2279020) and GABRG2 (rs211037) polymorphism in
drug resistance epilepsy
We also observed signiﬁcant difference at genotype as well as
allele frequencies of GABRA1 A > G polymorphism in drug resistant
versus drug responsive epilepsy patients for homozygous variant
GG genotype (P = 0.031, OR = 1.84, 95% CI = 1.05–3.23) and G allele
(P = 0.020, OR = 1.43 95% CI = 1.05–1.95, Table 2). However, in
GABRG2 588C > T we did not observe any signiﬁcant differences in
drug resistant versus drug responsive epilepsy patients either at
genotype or allele levels (Table 3). It suggests GABRA1 IVS11 + 15
A > G polymorphism modulates drug response as well as
susceptibility for epilepsy in north Indian epilepsy patients.
4. Discussion
In the present study, we found the involvement of GABRA1
IVS11 + 15 A > G polymorphism in increasing risk for developing
epilepsy as well as in modulating drug response in pharmacother-
apy, while GABRG2 588C > T was not found to be associated either
with epilepsy susceptibility or with drug resistance in north Indian
epilepsy subjects.
Upon comparing allele and genotype frequencies of variant of
GABRA1 IVS11 + 15 A > G in our control subjectswith that reported
for Chinese and Japanese population in Hapmap project data;
similar patterns were observed. Moreover, allele frequency of thisTable 4
GABRG2 588 C>T (rs211037); association studies in seizure disorder.
Phenotypes No. cases No. controls
Febrile convulsions 74 118
Generalized 77 83
All epilepsy 1361 656
Generalized 99 364
Generalized 121 284
Febrile convulsion 104 83
Febrile Convulsions 94 106
Generalized 135 154
Generalized 58 58
Febrile Convulsion 107 384
Generalized 96 384
All epilepsy 395 199
Generalized 227 199polymorphism was also similar to that reported in an Indian
population of Gujarati individuals (a state in western India) living
in Houston, TX (http://www.hapmap.org/cgi-perl/gbrowse/hap
map3B36/). However, allele and genotype frequencies of GABRG2
588C > T polymorphism show wide variation across different
world populations9,18 suggesting role of ethnic differences in
distribution of genetic variants. We minimized the inﬂuence of
genetic heterogeneity by inclusion of subjects fromnorth India and
distribution of genotypes in our control population for both the
polymorphisms were consistent with Hardy–Weinberg equili-
brium (HWE).
To the best of our knowledge, this is the ﬁrst report in which an
association of GABRA1 IVS11 + 15 A > G polymorphism was
observed with epilepsy susceptibility and drug resistance. This
is an intronic polymorphismwhich does not lead to any amino acid
change but it is possible that it alters the conformation of mature
protein by inﬂuencing alternative splicing. Several mutations in
this gene have also been reported to be involved in epilepsy
causation that result in loss of function of GABAA receptors via a
reduction in GABA expression and, accelerated deactivation.19
Another most widely studied single nucleotide polymorphisms
(SNPs) in the human GABAA receptor is GABRG2 588C > T gene
polymorphism present at position 588 of exon 5. It results in
synonymous or silent change asn196asn that does not affect the
sequence of the encoded protein, suggesting that this SNP exists in
linkage disequilibrium with other disease causing variants. An
earlier study has reported association of this synonymous variant
with febrile seizures in a cohort of 104 Taiwanese children
[P = 0.017, OR = 2.56, 95% CI = 1.01–6.50].9 However, we did not
ﬁnd association of this polymorphism either with epilepsyCountry of origin P-Value Reference
USA 0.8 23
Taiwan 0.002 9
UK and Ireland >0.11 24
UK 0.61
Ireland 0.95
Taiwan 0.009 20
Japan 0.5 25
Germany 0.5 18
China 0.07 26
UK 0.2 27
UK 0.6
India 0.37 Present study
India 0.519
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patient with febrile seizures was limited in our study subjects and
etiology of other sporadic epilepsies is different from febrile
seizure. Similarly studies in Caucasian and other populations also
failed to replicate its association in epilepsy patients (Table 4)
except in Taiwanese population.9,20 It suggests that association of
this polymorphism is population speciﬁc.
It is now well established that various AEDs mediate their
action through GABA binding.21 It is also hypothesized that target
receptor sites are somehow altered in the epileptic brain so that
they are much less sensitive to administered AEDs. Therefore, it is
possible that the association of GABRA1 IVS11 + 15 A > G poly-
morphism with refractory phenotype in our study may occur due
to changes in the structure and function of inhibitory GABAA
receptors. Excessive glutamate excitation and activation of drug
resistance genes may also contribute to changes in GABA receptor
conformation and loss of drug efﬁcacy.
Overall, results from our study suggest differential behavior of
subunits of GABAA receptor gene polymorphisms in epilepsy
susceptibility and its therapy. However, in addition to genetic
factors, there aremultiple causes of drug resistance in epilepsy that
include past treatment history22 and other clinical factors such as
type of epilepsy, duration of seizure, and number of seizures prior
to initiation of drug therapy.
Thus, our ﬁndings are supportive of the fact that different
subunits of GABAA receptor subtypes play differential roles in
epilepsy at multiple levels and may affect inter-individual
variation in drug response for AEDs used in the treatment of
epilepsy. Till now very few studies have explored role of these
genetic variants in epilepsy and multiple drug resistance; it would
be desirable to study them at functional level and also to replicate
them in larger cohorts.
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